The eCLEAR study (NCT03041012) safety findings in newly diagnosed HIV-1-infected adults are discussed in this video interview with Prof. Ole Schmeltz Søgaard (Aarhus University, Aarhus, Denmark). He discusses the findings from the eCLEAR study that evaluated the impact of the bNAb 3BNC117 and/or latency reversal with romidepsin (RMD) on HIV-1 persistence among individuals starting first-line INSTI-based ART regimens.
The abstract entitled: ‘The Impact Of 3BNC117 And Romidepsin Treatment at Art Initiation on HIV-1 Persistence’ (Abstract #479) was presented at Conference on Retroviruses and Opportunistic Infections (CROI) 2022 (Virtual), 12-16 February 2022.
Questions:
- What were the aims and design of the eCLEAR study? (0:05)
- What were the outcome measures and how well were they achieved? (1:35)
- What was observed in your findings? (2:29)
Disclosures: Prof. Ole Schmeltz Søgaard has nothing to disclose in relation to this video interview
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed as a highlight of CROI 2022.
